Sugi Predict

Sugi Predict / Compounds / SCHEMBL13192152

SCHEMBL13192152

SCHEMBL13192152

N#Cc1ccccc1OCc1cccc(O)c1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ MAOB P27338 1/20 0.45
▸ XDH P47989 2/20 0.45
▸ HTR2A P28223 1/20 0.44
▸ MRGPRX4 Q96LA9 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ SGMS2 Q8NHU3 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL448079 0.83 MAOB (0.57) ATML3MBTL1MAOBXDHALDH1A1
SCHEMBL28051292 0.83 ATM (0.51) ATML3MBTL1MAOBXDHMRGPRX4
SCHEMBL18959092 0.83 L3MBTL1 (0.51) ATML3MBTL1MAOBSGMS2MAPK1
SCHEMBL19427248 0.83 L3MBTL1 (0.51) ATML3MBTL1MAOBXDHMRGPRX4
SCHEMBL6357776 0.83 MRGPRX4 (0.53) L3MBTL1MRGPRX4SMN1; SMN2NPC1RAB9A
SCHEMBL19431639 0.80 L3MBTL1 (0.48) ATML3MBTL1MAOBXDHMRGPRX4
SCHEMBL19421176 0.80 L3MBTL1 (0.48) ATML3MBTL1MAOBXDHMRGPRX4
SCHEMBL3922233 0.79 SGMS2 (0.51) L3MBTL1MAOBXDHALDH1A1SGMS2
SCHEMBL28185508 0.79 MAOB (0.58) MAOBXDHMRGPRX4
SCHEMBL10431653 0.78 CYP2D6 (0.53) ATML3MBTL1MAOBSGMS2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2024-11-21 — — US disclosed
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2024-08-20 — — US disclosed
US-20230097422-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2023-03-30 — — US disclosed
CN-113121562-B Polycyclic compounds as inhibitors of bruton's tyrosine kinase 詹森药业有限公司 2022-09-13 — — CN disclosed
CN-113105475-B Inhibitors of bruton's tyrosine kinase and methods of use thereof 詹森药业有限公司 2022-09-09 — — CN disclosed
US-11319329-B2 Inhibitors of Bruton's tyrosine kinase and methods of their use JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 — — US disclosed
CN-113121562-A Polycyclic compounds as inhibitors of bruton's tyrosine kinase 詹森药业有限公司 2021-07-16 — — CN disclosed
CN-113105475-A Inhibitors of bruton's tyrosine kinase and methods of use thereof 詹森药业有限公司 2021-07-13 — — CN disclosed
US-20210101910-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2021-04-08 — — US disclosed
US-10934310-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2021-03-02 — — US disclosed
US-9624239-B2 Protein kinase inhibitors PHARMASCIENCE INC. (CA) 2017-04-18 — — US disclosed
US-9624239-B2 Protein kinase inhibitors PHARMASCIENCE INC. (CA) 2017-04-18 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2014029007-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2014-02-27 — — WO disclosed
US-20140045833-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2014-02-13 — — US disclosed
US-20140045833-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2014-02-13 — — US disclosed
WO-2012135944-A9 PROTEIN KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2014-01-09 — — WO disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed
WO-2012135944-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2012-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934310-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN ATM 254/4885L3MBTL1 3252/4885MAOB 505/4885
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN ATM 254/4885L3MBTL1 3252/4885MAOB 505/4885
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 ATM 253/4885L3MBTL1 2705/4885MAOB 658/4885
US-20230097422-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE ABL1, BTK, LYN ATM 254/4885L3MBTL1 3252/4885MAOB 505/4885
US-20140045833-A1 Protein Kinase Inhibitors LCK, BTK, TEC ATM 2104/4885L3MBTL1 3406/4885MAOB 2938/4885
US-20210101910-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 ATM 253/4885L3MBTL1 2705/4885MAOB 658/4885
US-11319329-B2 Inhibitors of Bruton's tyrosine kinase and methods of their use ABL1, BTK, MYLK2 ATM 253/4885L3MBTL1 2705/4885MAOB 658/4885
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK ATM 1161/4885L3MBTL1 2550/4885MAOB 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.